Eerik Kukebal

Cooley advised Kpler, a fast-growing data and analytics firm on a mission to build one platform for global trade intelligence, on its acquisition of Spire Global’s maritime business for approximately $241 million.

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.

Cooley advised Accel Partners as lead investor on the $20 million Series A financing of Lottie, a free service that helps families and retirees find the UK’s best care homes and retirement living communities. Partner Aaron Archer led the Cooley team advising Accel, a global venture capital investment firm investing in the growth of next-generation industries.

Cooley is advising Veritone, an artificial intelligence company, on its acquisition of Broadbean for $52 million.